Quantcast

Latest RNA Stories

2014-10-30 16:29:15

LA JOLLA, Calif., Oct. 30, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will report financial results and highlights for the quarter ended September 30, 2014 on Wednesday, November 5, 2014, after the U.S. financial markets close. Regulus will host a conference call and webcast on Wednesday, November 5, 2014, at 5:00 pm Eastern...

2014-10-29 08:33:08

Data Supportive of GEN-2, an RNAi Carrier for Therapeutic Treatment of Lung Cancer LAWRENCEVILLE, N.J., Oct. 29, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today announced the presentation of data related to TheraSilence(TM), the Company's lung-specific RNA delivery technology, at the miRNA World Conference Workshop on miRNA Delivery in Boston, MA. The data was presented by Dr. Khursheed Anwer, Celsion's Executive Vice President and Chief Scientific Officer, during a panel...

2014-10-28 04:22:38

DALLAS, October 28, 2014 /PRNewswire/ -- RnRMarketResearch.com adds RNA Interference Screening Trends 2014 market research and industry survey report to the Biotechnology section of its life sciences intelligence library. This market report summarizes the results of an industry-wide global web-based benchmarking survey on RNA interference (RNAi) screening and gene silencing carried out in October 2014. The questionnaire was compiled to meet the needs, requirements and...

2014-10-22 08:31:10

- Interim Results from Ongoing Study Demonstrate Human Proof-of-Concept and Underscore the Value of Regulus' microRNA Platform - LA JOLLA, Calif., Oct. 22, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has demonstrated human proof-of-concept with a microRNA therapeutic from an ongoing clinical study evaluating RG-101, a wholly-owned,...

2014-10-21 12:32:38

DUBLIN, Oct. 21, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global RNA Based Therapeutics Market (Technology, Application, End Users and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 A new report titled "RNA Therapeutics Market (technology, applications, end user and...

2014-10-14 16:27:09

LONDON, Oct. 14, 2014 /PRNewswire/ -- This BCC Research report provides an in-depth assessment of recent progress and future opportunities for RNA interference (RNAi) players in major therapeutic and drug delivery areas, including infectious diseases, cancer, inflammation/immune dysfunction, central nervous system (CNS) disorders, and cardiology/metabolism. Known simply as RNAi, this field has rapidly emerged as a fast-growing new market. This report also provides forecasts for market...

2014-10-14 08:32:24

-New Preclinical Results Increase Mechanistic Understanding of Targeting miR-103/107 for Metabolic Disorders and miR-21 for Renal Dysfunction in Alport Syndrome Patients- LA JOLLA, Calif., Oct. 14, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will present new preclinical data on multiple programs and an overview of its clinical portfolio at...

2014-10-07 16:26:26

DUBLIN, Oct. 7, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "RNA Analysis/Transcriptomics Market by Technology, by Application, by End-User - Global Forecast to 2019" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 The global transcriptomics market is expected to grow at a CAGR of 13.7% during the forecast period of 2014 to 2019 and is estimated to be worth $3,773.0 million by 2019. The transcriptomics market has blatantly grown...

2014-10-07 12:31:14

Agreement strengthens New England Biolabs' position as a key supplier to the RNA synthesis sector IPSWICH, Mass., Oct. 7, 2014 /PRNewswire/ -- New England Biolabs, Inc. (NEB(®)) has strengthened its position as a key supplier to the fast-growing RNA synthesis market by signing an agreement to supply critical reagents to TriLink BioTechnologies, Inc., a leading manufacturer of mRNA and long RNA for research, diagnostic and therapeutic applications. ?Under the terms of the agreement,...

2014-09-29 08:29:58

MARLBOROUGH, Mass., Sept. 29, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company's President and Chief Executive Officer, Dr. Geert Cauwenbergh, will present at the 13(th) Annual BIO Investor Forum on Tuesday, October 7, 2014 at 10:00 a.m. PST. Dr. Cauwenbergh will...


Latest RNA Reference Libraries

Brief Introduction To DNA Probes
2014-01-12 00:00:00

DNA probes help scientists to detect a specific gene in a long DNA sequence. According to Dr. Michael A. Pfaller, DNA probes are “single-stranded pieces of nucleic acid, labeled with a specific tracer (isotope, enzyme, or chromophore), that will hydrogen bond (hybridize) with complementary single-stranded pieces of DNA (or RNA) under the appropriate conditions of pH, temperature, and iconic strength.” The Foundation for Genomics and Population Health website has a helpful video about...

Caenorhabditis elegans
2014-01-12 00:00:00

Caenorhabditis elegans is a species of parasitic roundworm in the Nematoda phylum. It can be found in temperate regions, in many different areas of the world. It prefers to reside in nutrient rich soils. Its scientific name is derived from the Greek terms Caeno, meaning recent, rhabditis, meaning rod-like, and the Latin term elegans, which means elegant. It was first named by Maupas in 1900, but was not classified in the Caenorhabditis subgenus until 1952 by Osche. Caenorhabditis elegans...

Proceedings of the National Academy of Sciences
2012-05-29 11:19:42

The Proceedings of the National Academy of Sciences of the United States of America (PNAS) is a peer-reviewed scientific journal established in 1914 as the official journal of the US National Academy of Sciences. The first managing editor of the journal was mathematician Edwin Bidwell Wilson. As of May 2012, the editor-in-chief is Inder M. Verma. PNAS is published weekly in print, and daily online in PNAS Early Edition. The first issue of PNAS was published in 1915, and the journal...

Biophysical Journal
2012-05-28 10:08:02

The Biophysical Journal is a peer-reviewed scientific journal published biweekly by Cell Press on behalf of the Biophysical Society. It was established in 1960. The editor-in-chief is Edward Egelman. It covers all aspects of biophysics.  It is the leading international journal for original research in molecular, cellular, and system biophysics. Modern biophysics is a broad and rapidly advancing field encompassing the study of biological structures with a focus on mechanisms at the...

More Articles (5 articles) »
Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related